BR9911009A - Sulfonilcianamidas substituìdas, processo para sua produção e seu uso como medicamento - Google Patents

Sulfonilcianamidas substituìdas, processo para sua produção e seu uso como medicamento

Info

Publication number
BR9911009A
BR9911009A BR9911009-1A BR9911009A BR9911009A BR 9911009 A BR9911009 A BR 9911009A BR 9911009 A BR9911009 A BR 9911009A BR 9911009 A BR9911009 A BR 9911009A
Authority
BR
Brazil
Prior art keywords
ischemia
treatment
diseases
substituted
production
Prior art date
Application number
BR9911009-1A
Other languages
English (en)
Inventor
Andreas Weichert
Hans Jochen Lang
Stefan Petry
Jan-Robert Schwark
Heinz-Werner Kleemann
Sabine Faber
Hans-Willi Jansen
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR9911009A publication Critical patent/BR9911009A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Patente de Invenção: <B>"SULFONILCIANAMIDAS SUBSTITUìDAS, PROCESSO PARA SUA PRODUçãO E SEU USO COMO MEDICAMENTO"<D>. A invenção refere-se a compostos da fórmula (1) nos quais os símbolos têm o significado dado nas reivindicações. Os referidos compostos são inibidores do trocador de bicarbonato/cloreto, dependente de sódio, que pode ser usado como medicamentos para a profilaxia ou tratamento de uma ampla gama de doenças, por exemplo, o tratamento e/ou a profilaxia de infarto do miocárdio, angina pectoris, doenças causadas por isquemia, respiração deficiente, isquemia cardíaca, isquemia do sistema nervoso central e periférico e ataque apoplético, isquemia dos órgãos periféricos e membros e doenças nas quais a proliferação celular é uma causa primária ou secundária, no tratamento de choque, durante intervenções cirúrgicas e transplantes de órgãos ou para conservar e armazenar órgãos para transplante, a ser usado em intervenções cirúrgicas.
BR9911009-1A 1998-05-06 1999-04-30 Sulfonilcianamidas substituìdas, processo para sua produção e seu uso como medicamento BR9911009A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19820064A DE19820064A1 (de) 1998-05-06 1998-05-06 Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
PCT/EP1999/002940 WO1999057102A1 (de) 1998-05-06 1999-04-30 Substituierte sulfonylcyanamide, verfahren zu ihrer herstellung und ihre verwendung als medikament

Publications (1)

Publication Number Publication Date
BR9911009A true BR9911009A (pt) 2001-02-13

Family

ID=7866747

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911009-1A BR9911009A (pt) 1998-05-06 1999-04-30 Sulfonilcianamidas substituìdas, processo para sua produção e seu uso como medicamento

Country Status (27)

Country Link
US (1) US6573288B1 (pt)
EP (1) EP1076651B1 (pt)
JP (1) JP4546644B2 (pt)
KR (1) KR20010043304A (pt)
CN (1) CN1177829C (pt)
AR (1) AR016255A1 (pt)
AT (1) ATE293606T1 (pt)
AU (1) AU756844B2 (pt)
BR (1) BR9911009A (pt)
CA (1) CA2331863A1 (pt)
DE (3) DE19820064A1 (pt)
DK (1) DK1076651T3 (pt)
ES (1) ES2241326T3 (pt)
HK (1) HK1038008A1 (pt)
HR (1) HRP20000746A2 (pt)
HU (1) HU225377B1 (pt)
ID (1) ID28020A (pt)
IL (1) IL139264A (pt)
NO (1) NO317886B1 (pt)
NZ (1) NZ507964A (pt)
PL (1) PL344041A1 (pt)
PT (1) PT1076651E (pt)
RU (1) RU2221789C2 (pt)
SK (1) SK16582000A3 (pt)
TR (1) TR200003248T2 (pt)
WO (1) WO1999057102A1 (pt)
ZA (1) ZA200006166B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10206354A1 (de) * 2002-02-14 2003-08-28 Aventis Pharma Gmbh Verwendung von Inhibitoren des Natrium-abhängigen Chlorid-Bicarbonat-Austauschers zur Behandlung von thrombotischen und inflammatorischer Erkrankungen
US20030220383A1 (en) * 2002-02-14 2003-11-27 Aventis Pharma Deutschland Gmbh Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders
ITTO20060575A1 (it) * 2006-08-02 2008-02-03 Univ Pisa Inibitori di zinco proteinasi tioaril sostituiti e loro usi
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
IL98319A (en) * 1990-07-05 1997-04-15 Roussel Uclaf Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
TW215434B (pt) * 1992-03-07 1993-11-01 Hoechst Ag
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
FR2711368B1 (fr) * 1993-09-16 1996-01-05 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19804251A1 (de) 1998-02-04 1999-08-05 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament

Also Published As

Publication number Publication date
JP4546644B2 (ja) 2010-09-15
ATE293606T1 (de) 2005-05-15
DK1076651T3 (da) 2005-08-15
WO1999057102A1 (de) 1999-11-11
HRP20000746A2 (en) 2001-06-30
AR016255A1 (es) 2001-06-20
ZA200006166B (en) 2001-09-26
RU2221789C2 (ru) 2004-01-20
KR20010043304A (ko) 2001-05-25
IL139264A (en) 2004-07-25
DE19980787D2 (de) 2001-03-22
JP2002513785A (ja) 2002-05-14
HUP0102459A3 (en) 2002-12-28
HK1038008A1 (en) 2002-03-01
CA2331863A1 (en) 1999-11-11
NO20005549L (no) 2001-01-05
HUP0102459A2 (hu) 2002-03-28
EP1076651B1 (de) 2005-04-20
CN1305463A (zh) 2001-07-25
DE19820064A1 (de) 1999-11-11
AU756844B2 (en) 2003-01-23
CN1177829C (zh) 2004-12-01
AU5947999A (en) 1999-11-23
DE59911949D1 (de) 2005-05-25
US6573288B1 (en) 2003-06-03
HU225377B1 (en) 2006-10-28
TR200003248T2 (tr) 2001-03-21
PL344041A1 (en) 2001-09-24
IL139264A0 (en) 2001-11-25
PT1076651E (pt) 2005-08-31
EP1076651A1 (de) 2001-02-21
ES2241326T3 (es) 2005-10-16
NO317886B1 (no) 2004-12-27
SK16582000A3 (sk) 2001-06-11
NO20005549D0 (no) 2000-11-03
ID28020A (id) 2001-05-03
NZ507964A (en) 2003-06-30

Similar Documents

Publication Publication Date Title
BR9916732A (pt) Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa)
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
BR9814643A (pt) Inibidor de metaloprotease de ácido sulfona hidroxâmico aromático
BR0200782A (pt) Compostos para o tratamento da isquemia
BRPI9914741A (pt) n-(2-aril-proprionil)-sulfonamidas, usos e composições farmacêuticas contendo as mesmas.
Mallari et al. Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB
BR9811988A (pt) Derivados de n-alcanoilfenilalanina
BRPI9504791B8 (pt) composto de polipeptídeo e composição farmacêutica.
DK0559743T3 (da) Nye hydroxamsyre- og N-hydroxyurinstofderivater og deres anvendelse
PT948527E (pt) Novos derivados de ciclosporina sua preparacao e composicoes farmaceuticas que os contem
BR0204588A (pt) Derivados de n-alquil-adamantil-triazinil-benzamida
BR0316234A (pt) Hidroxiindóis, seu uso como inibidores de fosfodiesterase 4 e processos para a preparação dos mesmos
BR0215240A (pt) Derivados de calcona e seu uso no tratamento de doenças
BR0209855A (pt) Uso de compostos com atividade inibidora de nep/mp combinada na preparação de medicamentos
BR0014465A (pt) 1,1&#39;-bifenil-2-carbonamidas 2&#39;-substituìdas, processos para a sua preparação,seu emprego como medicamento bem como os preparados farmacêuticos contendo as mesmas
BR0014804A (pt) Composto, formulação farmacêutica, uso de um composto, método de profilaxia ou tratamento de uma arritmia, e, processo para a preparação de um composto
BR0001292A (pt) Desfolhante
BR9910573A (pt) Compostos antipicornavirais, preparação e uso dos mesmos
EA200200301A1 (ru) ЗАМЕЩЕННЫЕ α-ГИДРОКСИКИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ КЛЕТОЧНОЙ ГИБЕЛИ НА КЛЕТОЧНОМ ИЛИ ТКАНЕВОМ УРОВНЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ОБЛЕГЧЕНИЯ СОСТОЯНИЯ ПРИ ГИБЕЛИ КЛЕТОК У ЖИВОТНОГО, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ БОЛЕЗНЕЙ
BR0111440A (pt) Compostos eficazes como agonistas do (beta)2-adrenorreceptor bem como inibidores de pde4
EA199900542A1 (ru) Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)-азагетероциклиламида
BR9912218A (pt) Compostos obtidos de espécies de sálvia possuindo atividade antivirótica
BR0315820A (pt) Inibidores de integrase de hiv, composições farmacêuticas e métodos para a sua utilização
BRPI0215703B8 (pt) polimorfo de ácido 4-[2-[1-(2-etoxietil)-1h-benzidimazol-2-il]-1-piperidinil]etil]-a, a-dimetil-benzenoacético, preparado farmacêutico, e seu uso do polimorfo 1
BR9916669A (pt) Uso de derivados de ácidos 4-biarilbutìricos e 5-biarilpentanóicos substituìdos como inibidores de metaloproteases de matriz para o tratamento de doenças respiratórias

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1976 DE18/11/2008.